5 ms·

This one is one of the furthest ahead. Its the UK Oxford's ChAdOx1 vector for SARS-CoV-2. They partnered with AstraZeneca and I guess its now AZD1222. It was ve

This one is one of the furthest ahead. Its the UK Oxford's ChAdOx1 vector for SARS-CoV-2. They partnered with AstraZeneca and I guess its now AZD1222. It was very quickly far along because it was under development for years and years and was going through trials for MERS already when SARS2 hit. So they were almost instantly able to start trials on it with the pandemic. And unlike other vaccines they've been wanting to do, money poured in.

rladd 6y ago
The big problem with the Oxford ChAdOx1 nCoV-19 vaccine that I haven't seen discussed much is that it doesn't seem to work very well. Viral gRNA was detected in nose swabs from all animals and no difference in viral load in nose swabs was found on any days between vaccinated and control animals https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1 https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1 For a less technical write-up: https://www.forbes.com/sites/williamhaseltine/2020/05/16/did-the-oxford-covid-vaccine-work-in-monkeys-not-really/#2d2d53b83c71 https://www.forbes.com/sites/williamhaseltine/2020/05/16/did...